NeoGenomics: Fourth Quarter Earnings Overview

NeoGenomics Reports Fourth Quarter Financial Results

NeoGenomics Inc., headquartered in Fort Myers, Florida, announced a net loss of $9.9 million for the fourth quarter.

The company recorded a loss of 8 cents per share during this period. After adjusting for stock-based compensation and amortization, adjusted earnings were 6 cents per share.

These adjusted earnings surpassed analysts’ expectations, as a consensus of five analysts polled by Zacks Investment Research had predicted earnings of 4 cents per share.

NeoGenomics, which specializes in cancer diagnostic testing, generated $190.2 million in revenue for the quarter, beating the average analyst estimate of $188.5 million.

For the entire year, NeoGenomics reported a total loss of $108 million, or 84 cents per share, with annual revenue reaching $727.3 million.

Looking ahead, the company anticipates its full-year revenue to fall between $793 million and $801 million.